source
- Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye diseaseEthyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
- Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioToolsTreeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…